[go: up one dir, main page]

WO2009038012A1 - Composé hétérocyclique - Google Patents

Composé hétérocyclique Download PDF

Info

Publication number
WO2009038012A1
WO2009038012A1 PCT/JP2008/066400 JP2008066400W WO2009038012A1 WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1 JP 2008066400 W JP2008066400 W JP 2008066400W WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
pharmaceutically acceptable
acceptable salt
disease
hyperalgesia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066400
Other languages
English (en)
Japanese (ja)
Inventor
Toshio Nakamura
Shuji Saito
Mitsukane Yoshinaga
Hiroshi Ohta
Madoka Kawamura
Tomoko Ishizaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2009038012A1 publication Critical patent/WO2009038012A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un nouveau composé hétérocyclique représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, ou sur une préparation pharmaceutique contenant le composé ou le sel pharmaceutiquement acceptable en tant qu'ingrédient actif, qui présente une activité agoniste puissante sur un récepteur NPFF2 et est par conséquent utile pour la prévention ou le traitement d'une maladie telle que la douleur, une hyperalgésie, un trouble de l'alimentation, l'obésité, le diabète ou une maladie cardiovasculaire.
PCT/JP2008/066400 2007-09-18 2008-09-11 Composé hétérocyclique Ceased WO2009038012A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007241502 2007-09-18
JP2007-241502 2007-09-18

Publications (1)

Publication Number Publication Date
WO2009038012A1 true WO2009038012A1 (fr) 2009-03-26

Family

ID=40467829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066400 Ceased WO2009038012A1 (fr) 2007-09-18 2008-09-11 Composé hétérocyclique

Country Status (1)

Country Link
WO (1) WO2009038012A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130002991A (ko) * 2010-02-08 2013-01-08 엠에스데 오쓰 베.베. 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2018152134A1 (fr) * 2017-02-14 2018-08-23 Research Triangle Institute Modulateurs du récepteur ff de neuropeptide à base de proline

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135473A (ja) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd イミダゾ−ル縮合複素環化合物
WO2004058755A2 (fr) * 2002-12-24 2004-07-15 Biofocus Plc Bibliotheques de composes
JP2007504220A (ja) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ イミダゾ[1,5−a]ピリジン又はイミダゾ[1,5−a]ピペリジン誘導体および5HT2A受容体関連障害に対する薬剤の製造のためのその使用
JP2007509060A (ja) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135473A (ja) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd イミダゾ−ル縮合複素環化合物
WO2004058755A2 (fr) * 2002-12-24 2004-07-15 Biofocus Plc Bibliotheques de composes
JP2007504220A (ja) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ イミダゾ[1,5−a]ピリジン又はイミダゾ[1,5−a]ピペリジン誘導体および5HT2A受容体関連障害に対する薬剤の製造のためのその使用
JP2007509060A (ja) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130002991A (ko) * 2010-02-08 2013-01-08 엠에스데 오쓰 베.베. 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물
KR101661383B1 (ko) 2010-02-08 2016-09-29 머크 샤프 앤 도메 비.브이. 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2018152134A1 (fr) * 2017-02-14 2018-08-23 Research Triangle Institute Modulateurs du récepteur ff de neuropeptide à base de proline
CN110546136A (zh) * 2017-02-14 2019-12-06 研究三角协会 基于脯氨酸的神经肽ff受体调节剂
EP3583090A1 (fr) 2017-02-14 2019-12-25 Research Triangle Institute, International Modulateurs du récepteur ff de neuropeptide à base de proline
EP3583090A4 (fr) * 2017-02-14 2020-12-30 Research Triangle Institute, International Modulateurs du récepteur ff de neuropeptide à base de proline
US11491136B2 (en) 2017-02-14 2022-11-08 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
CN110546136B (zh) * 2017-02-14 2023-07-18 研究三角协会 基于脯氨酸的神经肽ff受体调节剂
US11826350B2 (en) 2017-02-14 2023-11-28 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
US12390446B2 (en) 2017-02-14 2025-08-19 Research Triangle Institute Proline-based neuropeptide FF receptor modulators

Similar Documents

Publication Publication Date Title
WO2010122980A8 (fr) Nouvel agoniste du récepteur ss de l'hormone thyroïdienne
WO2008136392A1 (fr) Préparation pour une administration orale
WO2009051119A1 (fr) Composé de pyrimidylindoline
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
WO2010026436A3 (fr) Composés pharmaceutiques
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2005044192A3 (fr) Composes triazole et utilisations associees
ZA200706021B (en) 1-thio-D-glucitol derivatives
WO2007135527A3 (fr) Composés de benzimidazolyle
UA94455C2 (en) Oxadiazolidinedione compound
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2005075425A3 (fr) Derives de bisaryluree
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2006124447A3 (fr) N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes
WO2009004082A3 (fr) Compositions pharmaceutiques anticonvulsives
WO2004052370A3 (fr) Utilisation de composes de la quinoline pour traiter des troubles lies au recepteur mch
WO2008156094A1 (fr) Dérivé de pyridazinone et inhibiteur de la pde le contenant comme ingrédient actif
WO2007065808A3 (fr) Agonistes du récepteur du neuropeptide-2
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2006020959A3 (fr) Heterocycles benzo-condenses substitues
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
WO2007105113A3 (fr) Application des antagonistes du récepteur crf1 à l'élaboration d'un médicament destiné au traitement du syndrome métabolique et/ou de l'obésité et/ou d'une dyslipoprotéinémie
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP